News
Patient Advocacy and Safety Conference
On 15th November 2016, more than 70 patient advocates and physicians from across the European Union attended the Patient Advocacy and Safety conference at the European Parliament in Brussels, Belgium.
The aim of the conference was to explore the topic of biologics and biosimilars and how different policies and practices across Europe impact on patients. Patient advocates raised concerns...
The Impact of Perianal Fistulae on a Crohn’s Disease Patient’s Quality of Life
EFCCA is embarking on exciting new research with Takeda to find out the impact of complex perianal fistulae on quality of life from Crohn’s disease patients’ perspective. Crohn’s disease patients both with and without perianal fistulae are invited to participate.
The questionnaire has been developed in cooperation with both experts and patient representatives. It includes questions about...
"IBD and Me" Teenage Transition Website
‘IBD and Me’
Teenage Transition Website
The transition from paediatric to adult care for young people living with IBD is ideally a staged process where young adults are gradually integrated into adult care. Viewing this transition as only an isolated ‘event’ can mean that young people reach adult services not possessing the skills required to self-manage their condition, and run the risk of...
Medical devices: more safety, more traceability
Stricter rules to ensure that medical devices such as breast or hip implants are traceable and comply with EU patient safety requirements were backed by MEPs on Wednesday. MEPs also approved laws to tighten up information and ethical requirements for diagnostic medical devices, e.g. for pregnancy or DNA testing.
Click here to read the full article.
Date of issue: 2017-04-05...
MEPs propose ways to make medicines more affordable
New medicine prices in the EU have risen over the past few decades, to the point of being unaffordable for many EU citizens and threatening the sustainability of national health care systems.
To strike a better balance between EU countries’ public health interests and those of the pharmaceutical industry, it calls for measures to improve the traceability of R&D costs, public funding...
Artificial Nutrition
PACIFHAN assists people travelling with Home Artificial Nutrition
“To travel is to live” Hans Christian Andersen
Imagine having a complex medical condition and treatment that enables you to live but, when it comes to travelling could pose problems if you find yourself in a medical situation unable to converse in the local language.
PACIFHAN is the International Alliance of Patient...
"From Health System Sustainability To Promoting Inclusive Growth" - Conference Report
The Lithuanian Health Forum Conference held in Vilnius was organised to consolidate and address the policies, goals, and objectives of the Vilnius Declaration’s “Sustainable Health Systems for Inclusive Growth”, which was developed and circulated internationally during the 2013 European Council Presidency.
Hosted by the Lithuanian Parliament, the conference on the 5th of September addressed...
Symposium on Innovations in Gastroenterology
We are pleased to announce a new initiative, "Innovations in Gastroenterology, 2017 Symposium” to be held in Tel Aviv, January 4-6, 2017.
This will be an exclusive event where gastroenterologists, researchers, and the pharmaceutical industry from all over the world can meet and learn about novel emerging technologies as well as practical gastroenterology and hepatology. We have mentioned this...
EFCCA AGM 2016
The 26th Annual General Meeting of EFCCA took place in Brussels from 27-28 May 2016. It gathered over 40 delegates for one and a half days of busy work and exchange of information. In addition to the dealing with the institutional work and activities, delegates of the GA also listened to a presentation made by Marek Lichota from Apetitie for Life about artificial nutrition, a subject of...
What you need to know about biosimilar medicines
The European Commission DG for Internal Market, Industry, Entrepreneurship and SMEs, have published 6 new language versions of the patient information document "What you need to know about biosimilar medicines", so that patients now have access to unbiased and reliable information in English, French, German, Italian, Polish, Portuguese and Spanish. The information...